685 related articles for article (PubMed ID: 20815170)
1. [TA90--new neoplastic marker].
Rudzki S; Gołyski J; Bronikowski P; Gołyska D
Pol Merkur Lekarski; 2010 Mar; 28(165):211-3. PubMed ID: 20815170
[TBL] [Abstract][Full Text] [Related]
2. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
3. Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients?
Vereecken P; Heenen M; Babar S; Van Baren N
J Eur Acad Dermatol Venereol; 2007 Feb; 21(2):278-80. PubMed ID: 17243984
[No Abstract] [Full Text] [Related]
4. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
5. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
6. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
7. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
9. Serum ceruloplasmin in melanoma patients.
Ros-Bullón MR; Sánchez-Pedreño P; Martínez-Liarte JH
Anticancer Res; 2001; 21(1B):629-32. PubMed ID: 11299817
[TBL] [Abstract][Full Text] [Related]
10. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
[TBL] [Abstract][Full Text] [Related]
11. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
12. Serum tumor markers for pancreatic carcinoma.
Fritsche HA; Gelder FB
Immunol Ser; 1990; 53():289-96. PubMed ID: 2100561
[TBL] [Abstract][Full Text] [Related]
13. [Current biological markers of cutaneous melanoma progression].
Stoitchkov K; Le Bricon T
Ann Biol Clin (Paris); 2000; 58(2):157-65. PubMed ID: 10760702
[TBL] [Abstract][Full Text] [Related]
14. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
[TBL] [Abstract][Full Text] [Related]
15. [Changes of immunosuppressive acidic protein (IAP) in patients treated with total-body hyperthermia].
Maeta M; Koga S; Shimizu N; Yoshioka H; Wakatsuki T
Gan To Kagaku Ryoho; 1985 Jan; 12(1):163-5. PubMed ID: 3966808
[No Abstract] [Full Text] [Related]
16. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
17. [The laboratory in the diagnosis of pancreatic cancer].
Boadas Mir J; Mora J; Farré Viladrich A
Gastroenterol Hepatol; 1999 Nov; 22(9):456-60. PubMed ID: 10638044
[No Abstract] [Full Text] [Related]
18. Serum markers in skin melanoma--preliminary study.
Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
[TBL] [Abstract][Full Text] [Related]
19. [Pancreatic cancer screening: mission impossible?].
Bartel M; Friess H
Z Gastroenterol; 2006 Nov; 44(11):1181-2. PubMed ID: 17115361
[No Abstract] [Full Text] [Related]
20. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
